PL3908282T3 - Leczenie raka z mutacjami genetycznymi gnaq lub gna11 za pomocą inhibitorów kinazy białkowej c - Google Patents
Leczenie raka z mutacjami genetycznymi gnaq lub gna11 za pomocą inhibitorów kinazy białkowej cInfo
- Publication number
- PL3908282T3 PL3908282T3 PL20703606.2T PL20703606T PL3908282T3 PL 3908282 T3 PL3908282 T3 PL 3908282T3 PL 20703606 T PL20703606 T PL 20703606T PL 3908282 T3 PL3908282 T3 PL 3908282T3
- Authority
- PL
- Poland
- Prior art keywords
- gna11
- gnaq
- inhibitors
- cancer
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789177P | 2019-01-07 | 2019-01-07 | |
| PCT/US2020/012542 WO2020146355A1 (en) | 2019-01-07 | 2020-01-07 | Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3908282T3 true PL3908282T3 (pl) | 2025-12-15 |
Family
ID=69467733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20703606.2T PL3908282T3 (pl) | 2019-01-07 | 2020-01-07 | Leczenie raka z mutacjami genetycznymi gnaq lub gna11 za pomocą inhibitorów kinazy białkowej c |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220305008A1 (pl) |
| EP (2) | EP3908282B1 (pl) |
| DK (1) | DK3908282T3 (pl) |
| FI (1) | FI3908282T3 (pl) |
| HR (1) | HRP20251266T1 (pl) |
| LT (1) | LT3908282T (pl) |
| PL (1) | PL3908282T3 (pl) |
| PT (1) | PT3908282T (pl) |
| RS (1) | RS67265B1 (pl) |
| WO (1) | WO2020146355A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250017921A1 (en) | 2020-09-08 | 2025-01-16 | Ideaya Biosciences Inc. | Pharmaceutical combination and tumor treatment |
| WO2022221586A1 (en) * | 2021-04-15 | 2022-10-20 | Ideaya Biosciences, Inc. | Combination therapy comprising a pkc inhibitor and a mek inhibitor |
| WO2024044774A2 (en) * | 2022-08-26 | 2024-02-29 | Ideaya Biosciences, Inc. | Methods of treating uveal melanoma with a pkc inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013531469A (ja) * | 2010-04-16 | 2013-08-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 黒色腫におけるgna11およびgnaqのエキソン4変異 |
| JO3589B1 (ar) * | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
-
2020
- 2020-01-07 WO PCT/US2020/012542 patent/WO2020146355A1/en not_active Ceased
- 2020-01-07 PL PL20703606.2T patent/PL3908282T3/pl unknown
- 2020-01-07 DK DK20703606.2T patent/DK3908282T3/da active
- 2020-01-07 LT LTEPPCT/US2020/012542T patent/LT3908282T/lt unknown
- 2020-01-07 PT PT207036062T patent/PT3908282T/pt unknown
- 2020-01-07 RS RS20250986A patent/RS67265B1/sr unknown
- 2020-01-07 EP EP20703606.2A patent/EP3908282B1/en active Active
- 2020-01-07 US US17/420,833 patent/US20220305008A1/en active Pending
- 2020-01-07 FI FIEP20703606.2T patent/FI3908282T3/fi active
- 2020-01-07 EP EP25186372.6A patent/EP4653052A2/en active Pending
- 2020-01-07 HR HRP20251266TT patent/HRP20251266T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3908282B1 (en) | 2025-07-02 |
| HRP20251266T1 (hr) | 2025-12-05 |
| DK3908282T3 (da) | 2025-10-06 |
| LT3908282T (lt) | 2025-10-27 |
| PT3908282T (pt) | 2025-10-15 |
| RS67265B1 (sr) | 2025-10-31 |
| EP4653052A2 (en) | 2025-11-26 |
| EP3908282A1 (en) | 2021-11-17 |
| FI3908282T3 (fi) | 2025-10-10 |
| WO2020146355A1 (en) | 2020-07-16 |
| US20220305008A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279587A (en) | Protein tyrosine phosphatase inhibitors and methods of using them | |
| IL286462A (en) | Protein tyrosine phosphatase inhibitors | |
| IL280099A (en) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins | |
| EP3980199A4 (en) | Sanitization and cleaning system for objects | |
| EP4079735A4 (en) | Compound for inhibiting and inducing degradation of egfr kinase | |
| EP3601285A4 (en) | THERAPEUTIC AGENT FOR THE INHIBITION OF PHOSPHODIESTERASE AND ITS RELATED DISORDERS | |
| SI3986897T1 (sl) | Inhibitor EGFR za zdravljenje raka | |
| PL3908282T3 (pl) | Leczenie raka z mutacjami genetycznymi gnaq lub gna11 za pomocą inhibitorów kinazy białkowej c | |
| EP3423451A4 (en) | INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING | |
| MX2021015826A (es) | Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| IL284434A (en) | Fibroblast activation protein inhibitors | |
| EP3983386A4 (en) | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | |
| EP4041212C0 (en) | MEK INHIBITORS FOR THE TREATMENT OF HANTAVIRUS INFECTIONS | |
| EP3377630A4 (en) | Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3 | |
| EP3439656A4 (en) | DOUBLE SMALL MOLECULE INHIBITORS OF TRPV4 AND TRPA1 FOR DISINFECTION AND ANESTHESIA | |
| PL3976597T3 (pl) | Inhibitory małocząsteczkowe kinazy indukującej nf-kb | |
| EP3262041A4 (en) | Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease | |
| CL2018001724A1 (es) | Terapia combinada de inhibidores de proteinas extra-terminales y bromodominio | |
| PT3915989T (pt) | Inibidor de jak e método de preparação do mesmo | |
| LT3532059T (lt) | Bromodomeno ir papildomo galinio baltymo inhibitorių derinio terapija | |
| EP3897622A4 (en) | Arginase inhibitors and methods of use | |
| EP3787629A4 (en) | CYCLINE-DEPENDENT KINASE INHIBITORS | |
| EP3768386A4 (en) | GENE THERAPY FOR THE TREATMENT OF BONE DISORDERS | |
| IL280343A (en) | Treatment of mucopolysaccharidosis iva | |
| EP4058015A4 (en) | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF |